Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Rating of “Buy” from Analysts

Zura Bio Limited (NASDAQ:ZURA) has received a consensus rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $15.80.

Several equities analysts have weighed in on ZURA shares. Chardan Capital dropped their target price on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research report on Friday, October 18th. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. HC Wainwright reissued a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research report on Monday, November 18th. Finally, Leerink Partners assumed coverage on Zura Bio in a research report on Monday, November 4th. They set an “outperform” rating and a $15.00 price objective for the company.

Insider Activity at Zura Bio

In related news, Director Parvinder Thiara sold 1,001,633 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zura Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new position in Zura Bio in the second quarter valued at approximately $43,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Zura Bio in the third quarter valued at approximately $46,000. Renaissance Technologies LLC lifted its stake in Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after buying an additional 5,900 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Zura Bio in the third quarter valued at approximately $62,000. Finally, Valence8 US LP purchased a new stake in Zura Bio in the third quarter valued at approximately $71,000. 61.14% of the stock is owned by institutional investors and hedge funds.

Zura Bio Stock Performance

Shares of ZURA opened at $2.88 on Friday. The company’s 50-day moving average price is $3.91 and its 200 day moving average price is $3.90. Zura Bio has a 12-month low of $2.00 and a 12-month high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, analysts forecast that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.